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incidence of TRM at 5 years and 10 years was 40.0% and
42.5%, respectively. Multivariate analysis showed that pa-
tients with more than 5% circulating blasts (HR2.06, p¼0.05)
and more than 80% bone marrow blasts (HR2.35, p¼0.04)
were associated with poor survival. AML (HR0.42, p¼0.02)
and conditioning regimen of BU+MEL+TBI (HR0.46, p¼0.03)
were associated with better OS and DFS. SCT from unrelated
donors (HR4.01, p¼0.01) was independently associated with
increased TRM.
In conclusion, our data demonstrate that these intensiﬁed
myeloablative conditioning could be alternative regimens that
provide a long term durable remission and disease-free sur-
vival in patients with refractory hematologic malignancies.Figure 1.419
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Introduction: Hematologic malignancies are largely dis-
eases of older age. Advances in graft versus host disease
(GVHD) prophylaxis utilizing post-transplant cyclophos-
phamide (PTCy) expanded the use of haploidentical he-
matopoietic cell transplantation and has encouraging results
in non-haploidentical hematopoietic cell transplantation as
well. The Hopkins’ regimen using ﬂudarabine, cyclophos-
phamide, total body irradiation and post-transplant cyclo-
phosphamide (FluCyTBI-PTCy) has been associated with low
toxicity, and low rates of acute and chronic GVHD. Limited
data exist comparing the toxicity of this regimen in older
versus younger patients. We hypothesized this regimen
would be well tolerated in older patients.
Methods: We performed retrospective analysis of patients
who underwent allogeneic hematopoietic cell trans-
plantation utilizing FluCyTBI-PTCy regimen between 2009
and 2014 at our institution. Patients were eligible regard-
less of donor type or source. Patients were divided on the
basis of age (50 vs <50) and their transplant outcomes
assessed. Kaplan-Meier models were used to estimate
overall, disease free and event free survival. Cumulative
incidence was estimated using the method of Klein and
Moeschberger.
Results: A total of 46 patients were identiﬁed, 23 patients
were < 50 years of age at the time of their transplant.
Diagnoses included AML (61%), ALL (13%), AA (4%), NHL
(9%), MDS (7%), CML (4%), and CLL (2%). Age at transplant
was 19e73 years, with a median of 49. Donor sources
included: unrelated (15%), haploidentical (83%) and
matched sibling (2%). At transplant, active disease was
present in 3 / 6 ALL patients, 11 / 28 AML patients, 3 / 4NHL patients and 1 / 2 CML patients. Median overall sur-
vival (OS) was 17.9 months. There was no evidence of a
difference in OS by age category (p ¼ 0.74) (Figure 1). Non-
relapse mortality (NRM) at 6.5 months was 16.1% in the
overall population and 20.7% in older patients. There were
no differences in NRM by age category (p ¼ 0.90). Also, no
differences were seen in the median DFS or EFS by age
group (data not shown). Overall cumulative incidence of
relapse at 6 months was 26.9%. Cumulative incidence of
relapse in younger patients was 35.7% and 18.3% in older
patients (p ¼ 0.76). Similarly there was no statistically
signiﬁcant difference in the acute or chronic GVHD rates in
the two cohorts (data not shown).
Conclusions: There is limited data on outcomes of Hopkin’s
non-myeloablative FluCyTBI-PTCy transplant regimen in
older patients. Here we demonstrate outcomes in older pa-
tients that are comparable to those in younger patients.
Though limited by the small number of patients our results
suggest this regimen is safe with low NRM, and favorable OS.
The regimen provides a potentially curative option for older
patients without excess toxicity.
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Myeloﬁbrosis (MF), either primary (PMF) or post poly-
cythemia vera (PV), or essential thrombocythemia (ET)
affects older patients. JAK2 inhibitors can ameliorate
symptoms but allogeneic hematopoietic stem cell trans-
plantation (HSCT) remains the only curative option. In
recent years, reduced intensity conditioning (RIC) has
become the preferred transplant modality for MF. Higher
rates of graft failure (GF) have been noted in patients with
MF undergoing allogeneic HSCT as compared to other
diseases. Whether due to an abnormal marrow microen-
vironment, organomegaly or an expanded clonal stem cell
pool, GF leads to dismal outcomes.
Between 2008 and 2014, 42 patients, median age 58 (range
40-68, 22 with PMF (5/22 transformed to AML), 20 with
Table 1
Characteristics of Patients with Graft Failure
Pt Diagnosis 1st graft Conditioning
1st graft
Graft
failure
Chimerism
CD3%/CD33%
2nd graft Same
than 1st
graft
Conditioning
2nd graft
Poor
graft
function
Chimerism
CD3%/CD33%
Outcome
from 2nd
graft
1 Post-ET MF VUD 10/10 Flu/Mel 2ry 10/98 VUD 10/10 no Flu/Cy/TBI200 no 100/100 Died, GVHD
2 Post-PV MF MMRD 9/10 Flu/Mel 1ry N/A VUD 9/10 yes Flu/Cy/TBI200 no 100/100 Alive 58 mo
3 PMF VUD 10/10 Flu/Mel/rATG 1ry N/A VUD 10/10 yes Flu/TBI200 yes 100/100 Died, GVHD
4 PMF
transformed
to AML
VUD 9/10 Flu/Bu/rATG 1ry N/A VUD 10/10 no Flu/Mel/Thio no 100/100 Alive 9 mo
5 Post-PV MF VUD 10/10 Flu/Mel 2ry 76/0 N/A N/A N/A no N/A Died,
pneumonia
6 PMF VUD 9/10 (DQ) Flu/Bu/rATG 2ry 0/100 N/A N/A N/A yes N/A Alive 3 mo
RIC-HSCT for MF still counts with signiﬁcant hurdles including primary and secondary GF. Use of unrelated, mismatched donors, RIC conditioning, and in vivo T-
cell depletion are potential risk factors for GF. Highly immunosuppressive non-myeloablative conditioning combining ﬂudarabine and low dose TBI promotes a
successful engraftment and can be used to salvage these patients.
Re-transplantation following graft failure is feasible. Further studies regarding optimal conditioning regimens are needed.
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ripheral blood stem cell (PBSC) transplantation. RIC included
Flu/Bu (5 patients), Flu/Bu/rATG (4 patients), Flu/Mel (20
patients) and Flu/Mel/rATG (11 patients). GVHD prophylaxis
was administered as FK/MTX (38 patients), CSA/MTX (1 pa-
tient) and CSA/MMF (3 patients). Sixteen were related do-
nors, and 26 unrelated; 36 donors were 10/10 and 6 were 9/
10 HLA matched. A JAK2 inhibitor was administered to 19
patients prior to HSCT. Mean and median OS were 24 and 13
months (range 1-79). Seventeen patients survived more than
2 years, and 7 are alive >5 years from second transplant.
Neutrophil engraftment, median 13 days (range 10-40);
platelet engraftment, median 20 days (range 11-87) with 10
patients failing to engraft platelets. For acute GVHD, 25 pa-
tients developed grade II-IV, and 8 patients developed
chronic GVHD. Six patients (14%) developed GF (4 primary, 2
secondary).421
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Background: Acute erythroid leukemia (AEL) is a rare sub-
type of AMLwith a relatively poor prognosis. Allogeneic stem
cell transplant (alloSCT) improves the outcomes of AEL;
however, only a small number (19%) of patients are typically
able to receive alloSCT (Blood 2010; 115: 1985).
Method: We retrospectively analyzed the outcomes of pa-
tients diagnosed with AEL (May 2008-January 2014) at Uni-
versity of Massachusetts Medical Center with respect to
alloSCT.
Results: Fourteen patients (3 females) were identiﬁed, me-
dian age was 73.2 years (range, 27-91) at diagnosis, 5 (35.7%)
were over the age of 80 years. At diagnosis median white
blood cell count was 1700 cells/mcL (range, 600-11,700),
hemoglobin was 9 grams/dL (range, 7.7-12.2) and platelet
count was 56,000 cells/mcL (range, 11,000-166,000). Six
(42.8%) patients had high risk disease based on the karyo-
type, 5 (35.7%) were tested for FLT3 and NPM1 mutation and
all of them were negative. Two (14.2%) patients had a prior
history of MDS. As initial therapy 6 (42.8%) patients received
a hypomethylating agent, 5 (35.7%) received induction
chemotherapy with high dose cytarabine/mitoxanthrone. Six
(42.8%) patients underwent alloSCT after receiving a reduced
intensity conditioning regimen. All of themwere in complete
remission prior to transplant. Median time to transplant was
4.9 months (range, 2.6-7.3). One of the six (16.6%) patients
developed acute GVHD, and 3 (50%) had chronic GVHD.
The median OS was 16.7 months (range, 0-36.5) of all AEL
patients. Patients whowere able to undergo an alloSCT had a
superior overall survival of 33months compared to 7months
without transplant (p¼0.036).
Conclusion: Our institutional experience conﬁrms that sur-
vival of patients with AEL can be signiﬁcantly improved by
allogeneic stem cell transplantation. Investigation of strate-
gies that will enable more AEL patients to receive allogeneic
SCT are warranted.422
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